PriceTargets.com logo

Benitec Biopharma - BNTC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.67
  • Forecasted Upside: 140.58%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.50 As of 03/19/2026 05:00 PM ET
▼ -0.18 (-1.54%)

This chart shows the closing price for BNTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Benitec Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTC

Analyst Price Target is $27.67
▲ +140.58% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Benitec Biopharma in the last 3 months. The average price target is $27.67, with a high forecast of $32.00 and a low forecast of $22.00. The average price target represents a 140.58% upside from the last price of $11.50.

This chart shows the closing price for BNTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Benitec Biopharma. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/18/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/9/2026TD CowenReiterated RatingBuy ➝ Buy
3/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$32.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/12/2026TD CowenReiterated RatingBuy ➝ Buy
11/24/2025HC WainwrightSet TargetBuy ➝ Buy$35.00 ➝ $32.00
11/14/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/4/2025Citizens JmpSet Target$22.00
11/4/2025CitigroupReiterated RatingOutperform ➝ Outperform
11/4/2025HC WainwrightBoost TargetBuy ➝ Buy$28.00 ➝ $35.00
11/4/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$20.00 ➝ $22.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025Zacks ResearchDowngradeHold ➝ Strong Sell
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/24/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$20.00
9/16/2025OppenheimerReiterated RatingOutperform ➝ Outperform$35.00 ➝ $29.00
7/7/2025TD CowenInitiated CoverageBuy
5/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
4/10/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.00
3/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
2/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
12/16/2024HC WainwrightInitiated CoverageBuy$28.00
12/13/2024Robert W. BairdInitiated CoverageOutperform$30.00
12/12/2024Robert W. BairdUpgradeStrong-Buy
12/3/2024GuggenheimReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
10/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight
10/16/2024OppenheimerInitiated CoverageOutperform$35.00
10/14/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $18.00
9/30/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$16.00 ➝ $16.00
9/12/2024GuggenheimInitiated CoverageBuy$17.00
7/22/2024Leerink PartnersUpgradeStrong-Buy
7/22/2024Leerink PartnersInitiated CoverageOutperform$13.00
6/13/2024Piper SandlerInitiated CoverageOverweight$30.00
4/22/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
2/15/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
1/24/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
9/26/2023Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$6.50
10/18/2022Citizens JmpInitiated CoverageMarket Outperform$68.00
9/23/2022HC WainwrightLower TargetBuy$170.00 ➝ $68.00
2/17/2022HC WainwrightInitiated CoverageBuy$170.00
(Data available from 3/20/2021 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Benitec Biopharma logo
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $11.50
Low: $11.24
High: $11.85

50 Day Range

MA: $11.64
Low: $10.35
High: $12.83

52 Week Range

Now: $11.50
Low: $9.85
High: $17.15

Volume

119,655 shs

Average Volume

197,406 shs

Market Capitalization

$395.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Benitec Biopharma?

The following Wall Street research analysts have issued stock ratings on Benitec Biopharma in the last year: Citigroup Inc., Citizens Jmp, HC Wainwright, Oppenheimer Holdings, Inc., TD Cowen, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for BNTC.

What is the current price target for Benitec Biopharma?

0 Wall Street analysts have set twelve-month price targets for Benitec Biopharma in the last year. Their average twelve-month price target is $27.67, suggesting a possible upside of 140.6%. HC Wainwright has the highest price target set, predicting BNTC will reach $32.00 in the next twelve months. Citizens Jmp has the lowest price target set, forecasting a price of $22.00 for Benitec Biopharma in the next year.
View the latest price targets for BNTC.

What is the current consensus analyst rating for Benitec Biopharma?

Benitec Biopharma currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BNTC.

What other companies compete with Benitec Biopharma?

Other companies that are similar to Benitec Biopharma include Sionna Therapeutics, Rapt Therapeutics, Iovance Biotherapeutics, Intellia Therapeutics and Nurix Therapeutics. Learn More about companies similar to Benitec Biopharma.

How do I contact Benitec Biopharma's investor relations team?

Benitec Biopharma's physical mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company's listed phone number is 510-780-0819 and its investor relations email address is [email protected]. The official website for Benitec Biopharma is www.benitec.com. Learn More about contacing Benitec Biopharma investor relations.